Bris­tol My­ers Squibb scores TYK2 OK; ARCH backs mR­NA plat­form play; Il­lu­mi­na’s $8B co­nun­drum; Siz­ing up Al­ny­lam's win; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Try­ing to keep up with all the news com­ing out of ES­MO? Well, oth­er than the spe­cial event sec­tion be­low, we’ll al­so be up­dat­ing the web­site through­out the week­end. If you pre­fer a sum­ma­ry, join Ar­salan Arif and John Car­roll for a vir­tu­al re­cap and analy­sis on Mon­day, when we will al­so pub­lish a spe­cial re­port.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.